Saturday, October 31, 2026
ExploreSearch
Via News
Markets

Walt Disney Stock Is 9% At Session Start On Friday

ViaNews Editorial Team

December 11, 2020

Walt Disney Stock Is 9% At Session Start On Friday

Shares of Walt Disney 9.55% to $169.46 at 10:11 EST on Friday, after two sessions in a row of . The New York Stock Exchange is 0.14% to $14,394.30, following yesterday's downward trend, This seems, , a somewhat trend today.

Walt Disney's last close was $154.43, 7.62% its 52-week high of $157.46.

Walt Disney's Sales

Walt Disney's sales growth is a negative 24.5% for the quarter and a decline by 9.5% for the next. The company's growth estimates for the quarter and the next is a negative 128.8% and a negative 51.7%, respectively.

Walt Disney's Revenue

Year-on-year quarterly revenue growth by 23.1%, now sitting on 65.39B for the twelve trailing months.

Walt Disney's Stock Top and Bottom Yearly Value

Walt Disney's stock is at $169.46 at 10:11 EST, its 52-week high of $157.46.

Walt Disney's Moving Average

Walt Disney's is way its 50-day moving average of $138.32 and way its 200-day moving average of $126.95.

Categories

Markets

Tags

Stock MarketStockWall StreetStock PriceStock Market NowNYSEMarket SessionNYAThe New York Stock ExchangeDISStock Price UpWalt Disney
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com